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ABSTRACT
USE OF TEXT DATA IN IDENTIFYING AND PRIORITIZING POTENTIAL DRUG
REPOSITIONING CANDIDATES
by
Majid Rastegar-Mojarad
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Professor Susan McRoy
New drug development costs between 500 million and 2 billion dollars and takes 10-15 years, with
a success rate of less than 10%. Drug repurposing (defined as discovering new indications for
existing drugs) could play a significant role in drug development, especially considering the
declining success rates of developing novel drugs. In the period 2007-2009, drug repurposing led
to the launching of 30-40% of new drugs. Typically, new indications for existing medications are
identified by accident. However, new technologies and a large number of available resources
enable the development of systematic approaches to identify and validate drug-repurposing
candidates with significantly lower cost. A variety of resources have been utilized to identify novel
drug repurposing candidates such as biomedical literature, clinical notes, and genetic data. In this
dissertation, we focused on using text data in identifying and prioritizing drug repositioning
candidates and conducted five studies.
In the first study, we aimed to assess the feasibility of using patient reviews from social media to
identify potential candidates for drug repurposing. We retrieved patient reviews of 180
medications from an online forum, WebMD. Using dictionary-based and machine learning
approaches, we identified disease names in the reviews. Several publicly available resources were
used to exclude comments containing known indications and adverse drug effects. After manually
reviewing some of the remaining comments, we implemented a rule-based system to identify
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beneficial effects. The dictionary-based system and machine learning system identified 2178 and
6171 disease names respectively in 64,616 patient comments. We provided a list of 10 common
patterns that patients used to report any beneficial effects or uses of medication. After manually
reviewing the comments tagged by our rule-based system, we identified five potential drug
repurposing candidates. To our knowledge, this was the first study to consider using social media
data to identify drug-repurposing candidates. We found that even a rule-based system, with a
limited number of rules, could identify beneficial effect mentions in the comments of patients. Our
preliminary study shows that social media has the potential to be used in drug repurposing.
In the second study, we investigated the significance of extracting information from multiple
sentences specifically in the context of drug-disease relation discovery. We used multiple
resources such as Semantic Medline, a literature-based resource, and Medline search (for filtering
spurious results) and inferred 8,772 potential drug-disease pairs. Our analysis revealed that 6,450
(73.5%) of the 8,772 potential drug-disease relations did not occur in a single sentence. Moreover,
only 537 of the drug-disease pairs matched the curated gold standard in the Comparative
Toxicogenomics Database (CTD), a trusted resource for drug-disease relations. Among the 537,
nearly 75% (407) of the drug-disease pairs occur in multiple sentences. Our analysis revealed that
the drug-disease pairs inferred from Semantic Medline or retrieved from CTD could be extracted
from multiple sentences in the literature. This highlights the significance of the need for discourselevel analysis in extracting the relations from biomedical literature.
In the third and fourth study, we focused on prioritizing drug repositioning candidates extracted
from biomedical literature which we refer to as Literature-Based Discovery (LBD). In the third
study, we used drug-gene and gene-disease semantic predications extracted from Medline abstracts
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to generate a list of potential drug-disease pairs. We further ranked the generated pairs, by
assigning scores based on the predicates that qualify drug-gene and gene-disease relationships. On
comparing the top-ranked drug-disease pairs against the Comparative Toxicogenomics Database,
we found that a significant percentage of top-ranked pairs appeared in CTD. Co-occurrence of
these high-ranked pairs in Medline abstracts is then used to improve the rankings of the inferred
drug-disease relations. Finally, manual evaluation of the top-ten pairs ranked by our approach
revealed that nine of them have good potential for biological significance based on expert
judgment.
In the fourth study, we proposed a method, utilizing information surrounding causal findings, to
prioritize discoveries generated by LBD systems. We focused on discovering drug-disease
relations, which have the potential to identify drug repositioning candidates or adverse drug
reactions. Our LBD system used drug-gene and gene-disease semantic predication in SemMedDB
as causal findings and Swanson’s ABC model to generate potential drug-disease relations. Using
sentences, as a source of causal findings, our ranking method trained a binary classifier to classify
generated drug-disease relations into desired classes. We trained and tested our classifier for three
different purposes: a) drug repositioning b) adverse drug-event detection and c) drug-disease
relation detection. The classifier obtained 0.78, 0.86, and 0.83 F-measures respectively for these
tasks. The number of causal findings of each hypothesis, which were classified as positive by the
classifier, is the main metric for ranking hypotheses in the proposed method. To evaluate the
ranking method, we counted and compared the number of true relations in the top 100 pairs, ranked
by our method and one of the previous methods. Out of 181 true relations in the test dataset, the
proposed method ranked 20 of them in the top 100 relations while this number was 13 for the other
method.
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In the last study, we used biomedical literature and clinical trials in ranking potential drug
repositioning candidates identified by Phenome-Wide Association Studies (PheWAS). Unlike
previous approaches, in this study, we did not limit our method to LBD. First, we generated a list
of potential drug repositioning candidates using PheWAS. We retrieved 212,851 gene-disease
associations from PheWAS catalog and 14,169 gene-drug relationships from DrugBank.
Following Swanson’s model, we generated 52,966 potential drug repositioning candidates. Then,
we developed an information retrieval system to retrieve any evidence of those candidates cooccurring in the biomedical literature and clinical trials. We identified nearly 14,800 drug-disease
pairs with some evidence of support. In addition, we identified more than 38,000 novel candidates
for re-purposing, encompassing hundreds of different disease states and over 1,000 individual
medications. We anticipate that these results will be highly useful for hypothesis generation in the
field of drug repurposing.
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Chapter 1: Introduction

1

1.1 Drug repositioning
Drug development is an expensive and time-consuming process. Developing a new drug costs
$500 million to $2 billion and takes 10-15 years [1]. In average, developing an oncology drug
takes 13 years and could cost 1.8 billion [2]. The enormous cost and lengthy process of drug
development underline the need for an alternative approach. A well-known approach to reducing
the cost and time of new drug development is drug repositioning [3] which is also known as drug
repurposing, re-profiling, re-tasking or therapeutic switching [4], [5] 1. Drug repositioning is the
process of identifying new indications for existing or failed drugs. Figure 1 shows time-lines for
drug discovery and drug repositioning process and highlights their differences [4].
a)
Target
screen

Candidate
compound

Tool
compound

Preclinical
development

Clinical
development

Therapy

Clinical or
computational
repositioning

Clinical
development

Therapy

Phase one
b)

Clinical or
marketed
drug

Figure 1: Comparing timelines of traditional drug discovery and drug repositioning [4] a) timeline in

traditional drug discovery process b) timeline of drug repositioning

Drug repositioning could play a significant role in the drug development process. Since
repositioning relies on previously approved drugs that already passed multiple toxicity tests in the
first phase (Figure 1-a) of drug development process and their toxicity profiles are already known
[2], drug repositioning candidates tend to be ready for clinical trials quickly and be reviewed by
Food and Drug Administration (FDA) faster [5]. Drug repositioning can decrease the traditional
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Shameer et al. [4] provided an overview of definition for drug repositioning and related methods which repurpose
pharmaceutical compounds.
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timeline from 10-17 years to only 3-12 years [5]. The significance of drug repositioning would be
more tangible knowing a small percentage of proposed drugs are able to pass the first phase
successfully. In average less than 10% [6] of proposed drugs pass the first phase. This rate for
oncology drugs is only 5% [2]. This low rate of success emphasizes the importance of drug
repositioning in reducing the cost and risk of drug development. There have been many efforts on
using repositioning which led to many successful discoveries.

1.2 Successful drug repositioning discoveries
One of the earliest drug repositioning cases is the use of reticulose for post-radiation effects in the
1950s [7], [8], [4]. Later in the 1980s, anti-malarial drugs were suggested as potential repurposing
candidates for rheumatoid arthritis and connective tissue disease [9]–[11]. One famous example
of drug repositioning is Pfizer’s sildenafil (Viagra) which was repositioned from angina treatment
to erectile dysfunction treatment in men in 1998 [12] and has recently been studied as a possible
treatment for Age-related Macular Degeneration [13]. Thalidomide is another example of drug
repositioning. Thalidomide first introduced as a sedative hypnotic [14] and then it was withdrawn
because of severe side-effects. Later, Thalidomide was re-introduced as an anti-cancer agent and
used for erythema nodosum leprosum and HIV wasting syndrome. In recent clinical trials,
Duloxetine, a medication for depression, was found to be effective in the treatment of stress urinary
incontinence in women [15]. Overall, from 2007-2009, approximately 30-40% of newly approved
drugs were repurposed medications [16].

1.3 Drug repositioning approaches
Typically, a new indication for an available drug is identified only by chance. However, new data
analytic technologies and a large number of available resources now enable the development of
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systematic approaches to identify and assess drug repositioning candidates with considerably
lower costs. Drug repositioning has been exhaustively studied, and various approaches have been
used [16]–[18] to identify novel drug repositioning candidates. They have used clinical data [19],
[20], genetic information [21]–[23], scientific literature [24]–[26], pathway information [27],
chemical structure similarity [28], and databases of clinical side effects [29].
Several meta-analyses of drug repositioning allow us to categorize the different approaches.
Dudley et. al. [30] reviewed computational methods for drug repositioning and categorized the
methods into two classes: drug-based and disease-based, based on whether drug or disease
perspective initiates the discovery. Wei et. al. [24] categorized the computational drug
repositioning methods into literature-based and ontology-based. Grau and Serbedzija [17] named
two types of drug repositioning: (1) identification of off-target drug actions and (2) identification
of relevance of a known drug target to a new disease. In general, drug repositioning methods can
be drug, disease or target oriented and can be further sub-classified into target-based, knowledgebased, signature-based, network-based and targeted-mechanism-based approaches [16], [31].
From an informatics perspective, we can categorize repositioning methods based on resources
utilized to extract drug repositioning discoveries. These resources include scientific literature,
clinical data, social media, and biological resources. The compound database PubChem [32] has
been used in several drug-repurposing studies [33]. Hoehndorf et al [34] implemented a system
that inferred novel associations between drugs and diseases by linking drug-gene associations in
the PharmGKB database to phenotype studies and animal models of disease. Moriaud et al [35]
presented a computational method that mined the Protein Data Bank [36] to identify drug
repositioning candidates. Several studies [24], [25], [34], [35], [37], [38] considered literature
mining for drug repurposing; this approach has been comprehensively reviewed elsewhere [39],
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[40]. Another valuable resource is social media. Although patients mostly use medically oriented
social media to describe adverse events associated with drugs [41], [42], their experiences may
help others to conceive of new indications for existing medications if their descriptions also
include beneficial effects. A well-known example is Zolpidem, an insomnia medication that,
through social media and patient reviews, was subsequently used for brain injury [43]. Leaman at
el [44] identified 157 beneficial effects from 3600 patient posts that could lead to drug repurposing.
The accuracy of these reported beneficial effects in social media requires additional confirmation,
but considering the value of drug repurposing and the huge amount of available social media data,
it is worthwhile to study this type of information and investigate the possibility of identifying
potential drug-repurposing candidates.
In the next chapter, we discuss related works in more detail.

1.4 Our contributions
This dissertation focuses on the use of text data in the drug repositioning process. We identify and
assess challenges and opportunities in using text data in two main tasks of drug repositioning:
1) identifying potential candidates for drug repositioning (DR) and
2) validating (or prioritizing) the potential candidates.
The contributions in this dissertation consist of the following:
•

Assessing the feasibility of using social media data in identifying potential drug repurposing
candidates. Our hypothesis is that this imperfect resource could support drug repurposing by
helping to identify unknown beneficial effects of drugs. This requires 1) gathering users’
comments in social media 2) identifying mentions of medication names (including generic names,
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synonyms, and brand names), instances of actual (rather than hypothetical) uses, and contrasting
these uses with the original indications found in published sources such as DrugBank.) We
examine two named entity recognition methods: 1) dictionary-based and 2) machine learning. We
develop a rule-based system to tag sentences with potential uses for drug repositioning. To evaluate
our system, we manually review the sentences which were tagged as positive to assess the
possibility of the potential drug repositioning candidates to be a true finding. As there is not any
gold standard for this task, we are not able to evaluate our system using more formal common
metrics such as precision, recall, and F-measure.
•

Comparing the number of relations that can be extracted from single sentences versus multiple
sentences. Our goal is to assess the number of relations which relation extraction systems might
be missing if they just focus on sentence-level analysis and to quantify the need for going beyond
sentence-level extraction and implementing a relation extraction system capable of both sentencelevel and discourse-level extraction. This study focusses on drug-disease relation extraction as a
case study. It uses two available resources, Semantic Medline and Comparative Toxicogenomics
Database (CTD), to infer drug-disease relations and then compare the coverage of these relations
in sentence level extraction versus discourse level extraction. This study provides a means to
compare the potential importance of considering both a) single sentences and b) multiple sentences
in relation extraction systems for the task of identifying drug repositioning candidates from text
data.

•

Evaluating the effectiveness of two new methods to prioritize potential drug repositioning
candidates identified by literature-based discovery (LBD) systems. In the first method, we consider
LBD systems which use semantic predications to generate a list of potential candidates. In this
study, we use predicates in semantic predications as the main metric to rank the candidates. We
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assess our method by comparing it against curated databases such as CTD and expert judgment.
In the second method, we train a binary classifier, using text surrounding the discoveries, to
classify the discoveries into desired classes. To evaluate the performance of these classifiers, we
calculate precision, recall, and F-measure.
•

Evaluating the use of published biomedical literature and clinical trials in ranking potential DR
candidates identified by Phenome-Wide Association Studies (PheWAS) [45]. We first generate a
list of potential DR candidates using PheWAS. Then, we develop an information retrieval system
to retrieve any evidence of those candidates appearing in the biomedical literature and clinical
trials. We use this information to prioritize our discoveries. Like previous methods, we ask an
expert to provide judgments to evaluate the performance of our ranking method.

7

Chapter 2: Background and Related Work
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2.1 Introduction
In this chapter, we review related works focusing on identifying potential DR candidates using
biomedical literature, social media and then the current studies on validation of potential DR
candidates.

2.1.1 Use of biomedical literature in drug repositioning
In the past decade, advances in high throughput biotechnology have shifted biomedical research
from individual genes and proteins to entire biological systems. To make sense of the large-scale
data sets being generated, researchers must increasingly be able to connect with research fields
outside of their core competence. In addition, researchers must interpret massive amounts of
existing knowledge while keeping up with the latest developments. One way researchers cope with
the rapid growth of scientific knowledge is to specialize, which leads to a fragmentation of the
scientific literature. This specialization or fragmentation of literature is a growing problem in
science, particularly in biomedicine. Researchers tend to correspond more within their fragments
than with the field’s broader community, promoting poor communication between specialties [46].
This is evidenced within the citations of such literature as authors tend to heavily cite those within
their narrow specialties. Interesting and useful connections may go unnoticed for decades. This
situation has created both the need and opportunity for developing sophisticated computersupported methodologies to complement classical information processing techniques such as
information retrieval [26].
Text mining can help bridge the gaps among subdisciplines by extracting new findings from the
literature and presenting them to researchers based on their research interest, without requiring
them to spend hours manually reading through new publications. There are systems, which go
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beyond that and after extracting findings from the literature, use the findings to suggest and assess
new hypotheses [47]. These systems support a process called Literature-Based Discovery (LBD)
[26]. LBD strives to find novel connections or correlations between concepts by using scientific
literature. LBD systems usually are comprised of the following steps:
1) Extracting findings (especially causal findings) from the scientific literature
2) Generating new hypotheses
3) Prioritizing and ranking the hypotheses
The first step usually carries out information extraction using natural language processing and
machine-learning techniques. To generate new hypotheses, Swanson’s ABC model [48] is a
common and well-known approach. The ABC model, which we explain later, cross-references
findings extracted from different articles and hypothesizes new findings. Validating these
hypotheses, manually by experts, is expensive and time-consuming which makes the role of the
third step within LBD systems extremely significant.
Similar to other domains, in the biomedical domain, a large pool of scientific literature is available
that has been utilized by researchers to design and implement a variety of LBD systems which has
led to valuable new discoveries [49]. In 1986, Don Swanson [50] introduced LBD and
hypothesized that fish oil may have beneficial effects in patients with Raynaud’s syndrome based
on the following findings that he concluded from two separate groups of literature:
1) Raynaud’s syndrome (A) patients have blood viscosity (B) disorder
2) Fish oil (C) can reduce blood viscosity (B).
Later the hypothesis was verified by clinical trials. This model is now known as Swanson ABC
model. Swanson implemented the model in a software system, called ArrowSmith [51], to
automate the hypothesis generation process. As the above example illustrates, the model contains
10

three entities/concepts, A as starting, B as linking, and C as target concept [52]. The discovery
process starts with mining associations between A - B and B - C from literature, then by combining
the associations with the same linking concept, a list of potential A-C associations is created. If
there is not any prior mention about a relation between A and C in literature, then a hypothesis of
association between A and C can be formulated which can be confirmed or rejected through human
judgment, laboratory methods or clinical investigations. The ABC model can be implemented in
two discovery manners, open and closed. In closed-discovery, the starting and target concepts are
determined by the user and the LBD system only identifies linking concepts. In the open-discovery
approach, the starting and target entities are not limited to any specific concept. This approach
usually generates a long list of potential relations. As mentioned, to reject or confirm each of these
relations, each candidate should be evaluated through clinical trials and laboratory experiments,
which are expensive and time consuming. LBD systems can facilitate and accelerate this step by
providing initial validation, using computational methods and existing knowledge, and narrowing
down the list to a more reasonable number of candidates. Otherwise, it is not cost effective for
other researchers or scientists to investigate the numerous numbers of candidates provided by
open-discovery methods.
There have been several LBDs implemented to generate hypotheses by following Swanson’s
paradigm, which has led to interesting and useful discoveries [53]. One of the most desirable
findings in the biomedical domain is drug-disease relation which could shed light on side effects
or new indications for an existing drug [54]. The latter one is known as drug repositioning which
we introduced previously and has been receiving much attention from pharmaceutical companies
and researchers. New uses connecting indomethacin and Alzheimer’s disease [55], somatomedin
c and arginine [56], anandamide and gastric cancer [57], psychiatric and somatic diseases [58],
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hypogonadism and diminished sleep quality [59], NF-kappaB and autism [60] are some of these
findings. LBD can be utilized to discover any type of relation such as disease candidate genes [61],
drug-drug interaction [62], drug mechanism [63], adverse drug reaction [64].
All LBD systems mentioned above have utilized a similar paradigm, but their approaches for
identifying starting, linking, and target concepts in text and extracting relationships between them
vary. To identify desired concepts in literature, usually LBDs rely on named entity recognition
systems [65] or medical subject heading (MeSH), terms assigned by experts to Medline abstracts
[66] that describe the content of the associated abstract. BITOLA [61] is one of the LBD systems
that uses assigned MeSH terms to each Medline abstract as concepts. After identifying concepts,
LBD can be used to extract the relationship between the concepts (causal associations). Some
common methods are: co-occurrence [61], association rules [67], term frequency–inverse
document frequency [68], Z-Score [69], and mutual information [70]. Other approaches are
available to identify associations between concepts and terms that do not co-occur with one another
in the biomedical literature [71][72]–[74]. Yetisgen-Yildiz and Pratt [52] survey these approaches
and Andronis et al. [54] reviews literature mining systems which have been applied to identifying
potential drug repurposing candidates.
Another approach for generating causal associations is using semantic predication [75]. A semantic
predication is a “subject – predicate – object” triple extracted from the literature. For example, in
the domain of drug repositioning, Subject and object are biomedical concepts from the UMLS
Metathesaurus [76] and predicate is a relation from the UMLS Semantic Network such as: affects,
causes, associated with, treats, etc. Semantic predications for the biomedical domain have been
extracted by a rule-based system called SemRep [77] and stored in a relational database called,
SemMedDB [78]. The latest version of this database contains more than 84 million predications,
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extracted from 25 million PubMed abstracts. This resource has been used in several studies to
facilitate knowledge discovery [79]–[81]. Hristovski et al. [75] proposed a method to use semantic
predication to enhance their LBD system, BITOLA. They concluded that using semantic
predications instead of co-occurrences generates a smaller number of false positive discoveries
and provides an explanation to support the findings. Ahlers et al [63] used semantic predications
in a closed-LBD system to discover connections between antipsychotic agents and cancer. Cohen
et al. [71] proposed using hyper dimensional computing in a LBD system based on semantic
predications. They suggested a method, called predication-based semantic indexing, to build a
sequence of semantic predications, which ultimately associate a drug to a disease as a novel
therapy. Cameron et al [53] proposed an automatic subgraph creation method, based on semantic
predications, to facilitate LBD. Workman and Stoddart [79] proposed using Semantic Medline as
a source for building a decision support system for point of care. The Natural Language Processing
Group at the Mayo clinic integrated semantic predications into a system, called Ask Mayo Expert
(AME), to retrieve the most relevant literature to support the evidence-based clinical decision
making process at point of care [80].

2.1.2 Use of Social media in Drug Repositioning
Social media provides a platform for patients to share their experiences with illnesses, medications,
and also medical centers [82]. Patient posts, usually written in an informal language, contain
hidden and valuable information. Owing to the massive amount of data derived from social media,
computerized systems are needed to analyze and extract useful information from patient
experience. Unlike scientific literature, these comments are usually written by non-expert users
who do not have any obligation to follow proper grammar in their comments or report observations
accurately. These differences make mining social media more complicated and challenging
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compared to scientific literature. Nevertheless, there have been several attempts to extract
knowledge from social media. Leaman et al [44] examined comments posted in a medical forum
to identify reported adverse drug events. After manually annotating a corpus of patient posts, they
used natural language processing methods to develop a system that extracted adverse drug
reactions from the text. Chee et al [83] studied patient posts on Health and Wellness Yahoo! groups
and applied common natural language processing methods to predict adverse drug events and
identify medications that might require further scrutiny by the Food and Drug Administration.
Freifeld et al [84] evaluated the correlation between adverse drug events reported in Twitter (where
statements are limited to 140 characters) and spontaneous reports received by a regulatory agency.
Rastegar et al [85] implemented a binary classifier to identify adverse drug reactions in tweets.
Sharif et al [86] proposed a sentiment classification framework to detect adverse drug reactions in
medical blogs and forums. Recently, Karimi et al [87] provided a corpus of 1321 medical forum
posts on patient-reported adverse drug events, which allows researchers to develop and evaluate
pharmacovigilance systems.
Although patients mostly use medically oriented social media to describe adverse events
associated with drugs [41], [42] , their experiences may help others to conceive of new indications
for existing medications if their descriptions also include beneficial effects. A well-known example
is Zolpidem, an insomnia medication that, through social media and patient reviews, was
subsequently used for brain injury [43]. Leaman at el [44] identified 157 beneficial effects, in 3600
patient posts that could lead to drug repurposing. The accuracy of these reported beneficial effects
in social media may be questionable, but considering the value of drug repurposing and the huge
amount of available social media data, it is worthwhile to study this type of information and
investigate the possibility of identifying potential drug-repurposing candidates [88].
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2.1.3 Validation and prioritizing potential drug repositioning candidates
As mentioned in the description of LBD above, one challenging and expensive task after
identifying potential drug repurposing candidates is validation. The discoveries can be confirmed
or rejected through human judgment, laboratory methods, or clinical investigations. The validation
could be facilitated with automated ranking and prioritizing of the potential candidates. There have
been several studies which proposed ranking algorithms, mostly as part of LBD systems. However
there have been several attempts to propose effective ranking methods [69], [70], [89] but this area
has been largely unexplored. Wren proposed an algorithm called average minimum weight (AMV)
[70]. The algorithm calculates a weight for each potential discovery (A-C) based on the strength
of A-B and B-C relations. The strength of each relation is calculated based on mutual information.
The algorithm considers all possible B concepts that have a relation with A and C in the calculation.
Another approach to rank the findings is proposed by Yetisgen-Yildiz and Pratt [69], [90]. They
used the number of B concepts that link A to C as the indication of a strong correlation. The
method, which called Linking Term Count with Average Minimum Weight (LTC-AMW), uses
AMV in case of a tie. Swanson et al. [89] introduced a measure to rank the discoveries based on
MeSH terms in literature called Literature Cohesiveness. AMV and LTC-AMV are generic and
can be used in different LBD systems, but these algorithms do not consider semantic predicates in
their calculation.
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Chapter 3: Use of social media in drug
repurposing
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3.1 Introduction
Social media provides a platform for patients to share their experiences with illnesses, medications,
and medical centers [82], [91]. Patient posts, usually written in an informal language, contain
hidden and valuable information. Owing to the massive amount of data derivable from social
media, computerized systems are needed to analyze and extract useful information from the
patient’s perspective. Unlike edited scientific literature, these comments are usually written by
non-expert users who may not follow proper grammar in their comments or report complete or
accurate observations. These differences make mining social media more challenging compared
to scientific literature. Nevertheless, there have been several successful attempts to extract
knowledge from social media. Leaman et al [44] examined comments posted in a medical forum
to identify reported adverse drug events. After manually annotating a corpus of patient posts, they
used natural language processing methods to develop a system that extracted adverse drug
reactions from the text. Chee et al [83] studied patient posts on Health and Wellness Yahoo! groups
and applied common natural language processing methods to predict adverse drug events and
identify medications that might require further scrutiny by the Food and Drug Administration.
Freifeld et al [84] evaluated the correlation between adverse drug events reported in Twitter (where
statements are limited to 140 characters) and spontaneous reports received by a regulatory agency.
Rastegar et al [85] implemented a binary classifier to identify adverse drug reactions in tweets.
Sharif et al [86] proposed a sentiment classification framework to detect adverse drug reactions in
medical blogs and forums. Recently, Karimi et al [87] provided a corpus of 1321 medical forum
posts on patient-reported adverse drug events, which allows researchers to develop and evaluate
pharmacovigilance systems.
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Although patients have mostly used medically oriented social media to describe adverse events
associated with drugs [41], [42], patients also sometimes report beneficial effects and their
experiences may also help others to conceive of new indications for existing medications. A wellknown example is Zolpidem, an insomnia medication that was subsequently used for brain injury
[43]. The miracle of this medication discovered in 1994, when a patient who suffered severe brain
injuries and went to coma, started to take Zolpidem as a sedative but it brought him back to life.
Since then, Zolpidem has been waking up several brain-injured patients from a vegetative state.
Leaman at el [44] identified 157 beneficial effects, in 3600 patient posts that could lead to drug
repurposing. These reported beneficial effects in social media may not always be completely
accurate (and possibly vulnerable to a placebo effect [44]), but considering the potential value of
drug repurposing and huge amount of available social media data, it is worthwhile to study this
type of information and investigate the possibility of identifying potential drug-repurposing
candidates. In this chapter, we consider the feasibility of using social media data in identifying
potential drug repurposing candidates. Our hypothesis is that this imperfect resource can be used
to identify candidates for drug repurposing by revealing new beneficial effects of medications
taken by patients and reported in social media. We collect patient reviews of 180 medications in
an online forum and then use common Named Entity Recognition approaches, we identify
beneficial or side effects reported by patients for each drug. We utilize public resources to
distinguish known side effects and beneficial effects from potentially new ones and then using a
rule-based system separate side effects from beneficial effects. To evaluate our approach, we
manually evaluate the finding.
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3.2 Data Sources
Data for this study is obtained from public resources to allow for replicability. We use four public
resources: WebMD [92], DrugBank [93], SIDe Effect Resource (SIDER) [94], and Unified
Medical Language System (UMLS) [76]. Below are brief descriptions of these resources and their
uses in this research.
WebMD is a collection of Web-based health-related services provided by a US corporation, that
consistently ranks as the top US health publisher in the United States [92]. It includes a forum
specifically for patients to share their experiences with medications. The comments are entered as
free text, and the length of comments is not subject to a character or word count limit. WebMD
[92] allows users to score three different aspects of the medication in their reviews: (1)
effectiveness, (2) ease of use, and (3) satisfaction. WebMD provides some basic information about
the users such as age, sex, and duration of treatment. Figure 2 shows a screenshot of a WebMD
review page. The patient comments from WebMD were the main material used in this study.
DrugBank is a bioinformatics and cheminformatics resource that provides drug information, such
as indication, synonyms, gene target, drug interactions, and structure. This database can be used
to identify the current indications of drugs and thus to identify mentions of potential new uses as
distinct from the prior ones.
SIDER, developed by Kuhn et al [94], contains information about 1430 marketed medications and
5880 side effects (140,064 drug-side effect pairs) extracted from public documents and package
inserts. The developers of SIDER retrieved adverse drug reaction and disease names from UMLS
to generate a dictionary of side effects. One can use SIDER to identify known side effects of drugs
mentioned in the comments.
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UMLS [76] integrates medical terminology and coding standards to help researchers and
developers create interoperable biomedical information systems. One can use UMLS resources to
create a dictionary of disease names that might potentially be treated by repurposed drugs.

Figure 2: A screenshot of WebMD web page which allows users to post a comment about a medication and rate it
based on effectiveness, ease of use, and satisfaction.
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3.3 Method
3.3.1 Creating a Table of Medications
In the first step, we create a table of medications frequently mentioned in social media, the
approved indications of these medications, and known side effects. For the list of medications, we
generate a list of the top 180 most frequently searched medications on WebMD. Through
DrugBank, we collect known and approved indications related to those medications. To locate the
drugs in DrugBank, we search drug names, synonyms and brand name entries. In the next step, a
list of known side effects for each drug is retrieved from SIDER. Finally, we retrieve all usergenerated reviews posted in WebMD about these medications. (WebMD categorizes reviews for
each medication, therefore distinguishing comments for each medication is a straightforward task
and there is not any need to locate or identify drug names in the comments.)

3.3.2 Identification of Medication Effects within Consumer Reviews
We next identify beneficial or adverse effects within the posted reviews. Beneficial effects would
be their impact on reducing some observed negative health condition, such as a rash. For
simplicity, we refer to such negative conditions as “diseases” although they might be symptoms
or observations related to a disease. Any mentions of disorders in the reviews are tagged by using
two disease named entity recognition (NER) approaches.
In the first approach, which can be considered a dictionary-based approach, a list of disease names
from UMLS is retrieved and a string-matching technique applied to identify any of the diseases
mentioned in the comments. The dictionary-based approach misses mentions that are either
semantic or grammatical variants of standard forms, so for these, a second approach was employed.
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The second approach uses MetaMap [95]. We evaluate these two approaches by comparing disease
names identified by each for the top ten most reviewed medications.
Since we are interested in newly reported uses, we discard reviews that contain only known adverse
effects for related medication, using the table we created previously. We then manually review
100 of the remaining comments to develop a list of textual patterns used to report beneficial effects
or indications. Using the textual patterns, we implement a rule-based system to tag the reported
beneficial effects within the comments. We report the frequency of each textual patterns in the
comments, before and after removing side effects and any previously known indications. In the
final step and as the evaluation, the comments that contained any of the textual patterns are
manually reviewed.

3.4 Results
3.4.1 Statistics of the medication table
The results of retrieving consumer generated posts for the top 180 most commonly searched drugs
in WebMD (mean number of posts per drug was 358) yielded 64,616 separate posts. Within this
set, Lisinopril (an angiotensin-converting enzyme inhibitor used to treat high blood pressure and
heart failure) had the most comments (n=2931), whereas metoclopramide (used to treat gastric
esophageal reflux disease) had the fewest comments (n=8). Table 1 shows the top 10 reviewed
medications and includes the three most frequently named diseases in the respective comments.
The dictionary created to capture all spelling variants of diseases provided in UMLS included
239,227 entries for 86,839 unique diseases.
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Table 1: Most reviewed medications in WebMD and most frequently named diseases in reviews.

Drug name

Number of
Reviews

Number of Disease names
Dictionarybased

Lisinopril

Hydrocodoneacetaminophen

Phentermine

Cymbalta

Lexapro

Effexor

2931

2684

1931

1651

1609

1568

288

MetaMap

1135

320

987

207

860

320

1063

269

864

290

943
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Most frequent disease names
Dictionarybased

MetaMap

Itch

Blood
pressure

High blood
pressure

Cough

Rash

Dry cough

Arthritis

Pain

Itch

Back pain

Chronic pain

Arthritis

Dry mouth

Dry mouth

Depression

Weight loss

Obese

Blood
pressure

Depression

Depression

Itch

Anxiety

Fibromyalgia

Weight gain

Depression

Depression

Itch

Weight gain

Panic attack

Anxiety

Depression

Depression

Drug name

Number of
Reviews

Number of Disease names
Dictionarybased

Tramadol

Trazodone

Topamax

Percocet

1404

1305

1191

1125

261

MetaMap

826

226

701

271

840

245

713

Most frequent disease names
Dictionarybased

MetaMap

Itch

Dizziness

Panic attack

Anxiety

Arthritis

Pain

Fibromyalgia

Back pain

Migraine

Dizziness

Depression

Insomnia

Dry mouth

Depression

Chronic
insomnia

Anxiety

Migraine

Migraine

Gist

Headaches

Memory loss

Tingling

Itch

Pain

Chronic pain

Abuse

Arthritis

Back pain

The dictionary-based NER approach identified 2178 disease names in the comments, whereas
MetaMap identified 6171 disease mentions. Table 2 shows the 10 most commonly named diseases
in the comments (after disambiguated terms and variations of diseases were removed manually).
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Table 2: Most frequently named diseases in reviews.

Dictionary-based
Disease

MetaMap

Count

Disease

Count

Depression

5602

Pain

9990

Itch

3594

Depression

4921

Migraine

1610

Blood pressure

4016

Dry mouth

1269

Weight gain

3778

Infection

1218

Dizziness

3484

Panic attack

1174

Anxiety

3323

Rash

1086

Headache

2216

Arthritis

905

Nausea

1977

Fibromyalgia

850

Relief

1671

Mood swing

730

Dry mouth

1279

Of the 180 drugs, 164 (91.1%) were listed in DrugBank but only 74 (41.1%) were listed in SIDER.
After filtering comments to remove text describing known indications and adverse drug events
from the list of recognized disease names, the top three most frequently named “new” diseases
from the text that remained are shown in Table 3 (note the overlap with Table 1).
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Table 3: Most-reviewed medications in WebMD and most frequently named diseases in the reviews after removing
known indications and adverse drug events.

Drug name

Lisinopril

Hydrocodoneacetaminophen

Phentermine

Cymbalta

Lexapro

Number of Disease names

Most frequent new disease
names

Dictionarybased

Dictionarybased

280

320

195

320

269

MetaMap

1124

987

834

1063

864
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MetaMap

Itch

Blood
pressure

High blood
pressure

Cough

Rash

Dry cough

Arthritis

Pain

Itch

Back pain

Chronic pain

Arthritis

Depression

Weight loss

Obese

Blood
pressure

High blood
pressure

Sleeping

Depression

Depression

Itch

Anxiety

Fibromyalgia

Weight gain

Depression

Depression

Itch

Weight gain

Drug name

Effexor

Tramadol

Trazodone

Topamax

Percocet

Number of Disease names

Most frequent new disease
names

Dictionarybased

Dictionarybased

290

200

196

271

245

MetaMap

943

670

609

840

713
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MetaMap

Panic attack

Anxiety

Depression

Depression

Itch

Dizziness

Panic attack

Anxiety

Fibromyalgia

Pain

Chronic pain

Back pain

Migraine

Headache

Chronic
insomnia

Depression

Migraine

Anxiety

Fibromyalgia

Headache

Migraine

Migraine

Gist

Headaches

Memory loss

Tingling

Itch

Pain

Chronic pain

Abuse

Arthritis

Back pain

3.4.2 Statistics of Textual Patterns
We identified 18 textual patterns used (or can be used) to report beneficial effects and then counted
the frequency of them in the reports. The frequencies of the top ten most common are shown in
Table 4.
Table 4: Textual patterns to identify drug repositioning candidates.

Pattern
I use * for

Count
307

Example drugs and comments2
Methadone: I use this for diabetic neuopathy. works well with very
little side effects.
Percocet: I use this for M.S. pain
Percocet: I use this med for peripheral neuropathy pain.

I use it for

42

Cymbalta: My use of Cymbalta is two fold. I use it for depression
and fibromyalgia pain.
Spironolactone: I use it for acne. Go figure it works
Promethazine: I use it for gastroparesis. I also use it for sleep 4 or 5
times a month

It helps
with

131

Nucynta: It helps with my pain from surgery
Percocet: it helps with my back pain, better then any drug
Klonopin: I like this medication it helps with my anxiety.

It help with

11

OxyContin: it help with muscle spasms
Neurontin: i had drop foot and much pain. it help with the pain
along with the 3 epidurals i receiveed in my spine.

2

Consumer comments are shown exactly as they appeared on the WebMD site.
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Pattern

Example drugs and comments2

Count

Cymbalta: i started this medication years ago. not only did it help
my depression, it help with my auto immune, muscle and nerve
pain.
I take it

1,161

Nucynta: I take it for severe headache and neck pain from arthritis,
bulging disks, and bone spur in my neck (cervical spine)
Methadone: I take it for chronic pain it helps a lot
Flexeril: I take it for muscle spasms related to fibromyalgia.

I take it for

91

Methadone: I take it for chronic pain it helps a lot
Methadone: I take it for degenertive disk deteration in my neck.
Hydrocodone-acetaminophen: i take it for my scholiosis of my
back

It works for

258

Methocarbamol: It works for my muscle tension, but gives me a
headache.
Diazepam: it works for my pain weal good
Tramadol: It works for my Arthritis Pain.

It is useful
for

0

…

Useful for

18

Methadone: very useful for chronic and severe pain associated with
fibromyalgia/rheumatoid arthritis.
Effexor: I have been reading the reviews of this med. I have been
using it for 1.5 yrs and has been very useful for my depression.
Ultram: this med has been very useful for my hip and back pain.

Prescribed
for

319

Percocet: I was prescribed for kidney stones. definately took the
pain away and very high.
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Pattern

Example drugs and comments2

Count

Zoloft: I feel like the antidepressant is used in conjunction with my
cymbalta which I am prescribed for both depression and
fibromayalgia.
Celebrex: I was prescribed for knee pain following surgery for torn
muniscus.

Table 5 shows the frequency of the patterns after removing the comments that referred to only
known side effects or indications.

Table 5: Frequency of common textual patterns after removing known indications and adverse drug effects.

Pattern
I use * for

Count
171

Example drugs and comments3
Flector: it’s not so bad. I use them for stress headaches only if I
have a mild headache
Hydroxyzine: I use this drug for itching attacks and it works fast
and effective for me.
Elavil: I use this medication for restless leg syndrom

I use it for

23

Promethazine: I use it for gastroparesis.i also use it for sleep 4 or 5
times a month
Amitriptyline: I use it for ic
Seroquel: I m in love with seroquel its amazing! I use it for sleep
and I wake up refreshed

It helps
with

72

Neurontin: it helps with numbness in my legs and arms
Neurontin: I was diagnosed with rsd in from a fall on the ice. It
helps with controlling the pain;

3

Consumer comments are shown exactly as they appeared on the WebMD site.
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Pattern

Count

Example drugs and comments3
Seroquel: although it helps with my depression I have gained over
50lbs

It help with

6

Oxycontin: it help with muscle spasms
Hydrocodone-acetaminophen: it is ok I think and it help with my
back pian.
Neurontin: I had drop foot and much pain. It help with the pain
along with the 3 epidurals I receiveed in my spine.

I take it

729

Methadone: I take it for chronic pain it helps alot
Pristiq: I take it for depression and ptsd as well as for chronic pain
from failed cervical fusion.
Zoloft: I have taken it for three years almost and when I take it my
depression worsens rather in the summer when I wouldnt take it I
was the happiest

I take it for

48

Percocet: I take it for pain after a shoulder surgery and it works
Buspar: I take it for stress.
Effexor: I take it for depression.

It works for

155

Pristiq: I do not think it works for me makes me very consipated
and I think it makes the back of my legs hurt in the muscle part.
Metformin: I take it before bed no sideeffect so for taking one
month hope it works for me yes I am scared
Flexeril: back problems healed up then came right back. overall it
works for a little while.

Useful for

13

Effexor: I have been reading the reviews of this med. I have been
using it for 1.5 yrs and has been very useful for my depression.

31

Pattern

Example drugs and comments3

Count

Hydrocodone-acetaminophen: this med. is useful for short term
relief of pain.
Ultram: this med has been very useful for my hip and back pain.
Prescribed
for

0

…

A manual review of the remaining comments identified five drugs with potential for repurposing
(see Table 6).

Table 6: Example comments suggesting the possibility of drug repositioning.

Medication

4

Indication

Adverse effect

Patient comments4

Methadone

Dry cough, drug
withdrawal
syndrome, opioid
type drug
dependence, and
pain

Amenorrhea,
phlebitis,
sneezing,
suffering,
withdrawn,
hypomagnesemia,
urticaria,
rhinorrhea, fever,
spasm, …

I use this for diabetic
neuopathy. Works well with
very little side effects.

Elavil

Depression, chronic
pain, irritable bowel
syndrome, sleep
disorders, diabetic
neuropathy,
agitation and
insomnia, and
migraine
prophylaxis

None in SIDER

elavil is an old school
antidepressant that is now
considered a dirty drug
because of its undesired side
effects. one of the
unintended side effects is to
relax the skeletal muscle
tissue. I use elavil off label
to treat my tmj

Consumer comments are shown exactly as they appeared on the WebMD site.
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Medication

Indication

Adverse effect

Patient comments4

Spironolactone

Low-renin
hypertension,
hypokalemia, and
Conn syndrome

Hyperkalemia,
amenorrhea,
urticaria,
epidermal
necrolysis,
anaphylaxis,
fever, toxic
epidermal
necrolysis,
lethargy, nausea,
…

I use it for acne. go figure it
works

Strattera

Attentiondeficit/hyperactivity
disorder, alone or in
combination with
behavioral
treatment

None in SIDER

I was prescribed this
medication for slight adhd
with off label anxiety help.

Viibryd

Acute episodes of
major depression

None in SIDER

It even helps my migraines
somewhat (maybe it will be
off label in the future for
migraine prophylaxis)

3.5 Discussion
3.5.1 Comparison of MetaMap Versus a Dictionary-Based Approach
MetaMap is a sophisticated tool that uses natural language processing and machine learning
methods; thus, it is not surprising that it is more accurate than the dictionary-based approach.
MetaMap, to some extent, addresses some general concerns such as disambiguation, misspelling,
and word normalization, but none of these is addressed in the dictionary-based approach. For
example, in the phrase “My stomach and back hurts to sit, lay down, or stand,” the dictionarybased approach would tag “down” as a disease because of overlap with the “genetic disorder down
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syndrome.” As Table 2 shows, MetaMap recognized about three times the number of disease
names as compared to the dictionary-based approach. The main reason for this difference is word
normalization in MetaMap. The dictionary-based approach is limited by its requirement for exact
matches—for example, a dictionary that contains only “dizzy” would not detect “dizziness” as a
relevant word. In contrast, MetaMap uses stemming and lemmatization to normalize words. The
main advantage of dictionary-based mapping over MetaMap is its speed (the dictionary-based
approach is considerably faster).

3.5.2 Using Patient Comments for Drug Repurposing
The reviews commonly described general disorders such as pain, itching, and headache. This is
expected because comments usually are not authored by medical experts. We observed that
patients more often tend to report adverse drug events instead of beneficial effects, as some of the
previous studies reported a similar trend [44]. For example, in the corpus provided by Leaman et
al [44], they annotated 157 beneficial effects in 3600 posts, while they found 1260 adverse drug
events. Nevertheless, some patient comments contain beneficial effects of medication, which
makes social media a useful resource for drug repurposing. This imbalanced distribution makes
identifying beneficial effects more difficult, however, especially for training a classifier. Our
results (see Tables 4, 5, and 6) suggest that an effective approach for this task would be to recognize
the textual patterns that people used to report beneficial effects (eg, “I use [drug] for [disease]”).
For example, in a review of Viibryd, a user mentioned, “It even helps my migraines somewhat,”
clearly noting a beneficial effect of the drug, which could be captured by our rule-based system.
Similar to other computational drug repurposing approaches, these findings need to be reviewed
manually by experts and then confirmed or rejected by laboratory tests or clinical trials.
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3.6 Limitations
There are some known limitations to this study. Analysis of the patient comments, which are
written in an informal manner, obviously needs a system that can handle spelling and grammatical
errors. The current implementation does not address these issues.
Our system covered only simple textual patterns, although the examples in Tables 4 and 5 highlight
the need to decode complex patterns. A simple pattern-matching system obviously is insufficient
for a statement such as “I use it for nose allergies and it does not clear up my nostrils.” A system
should be able to handle negation and coreference.
Another limitation of this study was that comments originated from only one forum. Other social
media sites such as Yahoo! Answers, PatientsLikeMe [96], and even Twitter have similar
information, which could be studied. In addition, using only one resource for known side effects
and one for indication was another limitation. In Table 3, there are several known indications and
adverse drug events, which highlight this limitation.
In this study, we were not able to evaluate our system using measures such as precision or recall
because of the lack of an annotated corpus.

3.7 Summary
We assessed the feasibility of using social media to identify drug-repurposing candidates. After
collecting patient reviews of medications from WebMD, we compared dictionary-based and
MetaMap approaches to identify disorders mentioned in the reviews. Reviews describing known
indications or known adverse drug events were excluded, and the remaining reviews were searched
for textual patterns commonly used to report beneficial effects. Although the most commonly
reported disorders were nonspecific (eg, pain, itching, headache), we nevertheless showed that

35

consumer comments contain beneficial effects of medication and have the potential to be used for
drug repurposing. Our textual patterns were able to capture some beneficial effects, but there is a
need for a more complex and sophisticated system to identify complex mentions of beneficial
effects in social media, such as those involving negation or co-reference.
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Chapter 4: Prioritizing potential drug
repositioning candidates extracted from
biomedical literature
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4.1 Introduction
In this chapter, we discuss literature-based discovery (LBD) and how to prioritize potential drug
repositioning candidates generated by LBD. This chapter consists of three separate studies. In the
first one, we study the effect of discourse-level and sentence-level analysis for relation extraction,
which is one of the main components in LBD systems. In the second and third studies, we propose
and evaluate two prioritizing algorithms to rank potential drug repositioning candidates generated
by LBD.

4.1.1 Discourse-level vs Sentence-level analysis for Relation Extraction
Information extraction (IE) aims to automatically extract information from text. To understand and
extract information from text, IE systems should look at the text as a whole and not just individual
sentences. Researchers in the discourse domain agree that usually sentences/clauses are not
understood in isolation [97]. IE researchers have studied discourse-level analysis [98] for
applications such as question answering and dialogue generation. One important aspect of
discourse-level analysis is identifying relation between sentences (clauses), called discourse
relations, such as contrast or explanation-evidence [97].
Two main tasks in IE are named entity recognition (NER) and relation extraction. In relation
extraction, IE systems identify the relation between two or more entities where the entities could
span multiple sentences. Identifying relations that span multiple sentences needs discourse-level
analysis to interpret context dependent aspects of meaning such as coreference resolution.
The goal of the first study in this chapter is to assess the need for discourse-level analysis for
relation extraction and evaluate the amount of information that IE systems would miss if they just
focus on the sentence level. To perform this experiment, firstly, Semantic Medline [78] is used to
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generate a list of potential drug-disease repositioning candidates. Then, we used Medline abstracts
to find evidence of these drug-disease co-occurrences, using two methods, one based on sentences
and the second based on discourse-level information.

4.1.2 Prioritization of LBD generated candidates
Once the potential novel findings are discovered by LBD systems, it is necessary to eliminate the
false positives, and identify only true findings (novel discoveries). Distinguishing novel
discoveries from the others is not a trivial task. Typically, the LBD method consists of two steps:
1) extracting and mining relations from the text, and 2) eliminating the false positives and
identifying only the true relations. As a final step, however, it is also important to have a rigorous
validation of the candidate relations before we proceeding to laboratory or clinical investigations,
since these are not only expensive but also time consuming. The effectiveness of a LBD system,
therefore, lies in its rigorous validation. Most prior studies lack such vigorous validation, including
ranking of the generated candidates generated through LBD process. Though there are a few prior
attempts [63], [71] in this direction, this area has been largely underexplored.
In the second part of the study, first we propose and evaluate the effectiveness of two predicatebased ranking methods for prioritizing potential drug repositioning candidates generated by LBD.
Then we propose a prioritization method based on context.
We discuss the methods and results of each study separately.

4.2 Methods for Generating Candidates from single or multiple sentences
The study contains two steps: 1) generating a list of drug-disease pairs based on LBDs and 2) using
the discoveries to evaluate the drug-disease relation extraction by comparing the extractions from
a single sentence to those from multiple sentences.

39

4.2.1 Generating drug-disease pairs
In the first step, a list of potential relations between drugs and diseases is generated following
Swanson’s model [48]. As discussed in Chapter 2, according to Swanson’s model if one scientific
study notes a correlation between concept A (Starting concept) and concept B (Linking concept),
and another study mentions a correlation between concept B and concept C (Target concept), then
there might be a correlation between concept A and C. In our study, drug is the starting concept
and disease is the target concept, a type of gene serves as a conceptual link between the two.
We use semantic predications from SemMedDB as a source of these two types of links [75]. For
example, from the following two predications:
Flecainide (Drug)

INTERACTS WITH

SCN5A (Gene)

ASSOCIATED WITH

SCN5A (Gene)
Heart Failure (Disease)

the system generates Flecainide-Heart Failure as a potential new drug-disease pair. Figure 3
shows the architecture of the overall LBD process.

Figure 3: Architecture of our LBD system. In this system, starting concept is a drug, the linking concept is gene, and the target is
a disease that leads to drug-disease discoveries. Our system uses Semantic predications as evidence of correlation between the
concepts.

There are two major reasons for our choice of using semantic predication to generate LBDs

40

1) semantic predication takes biological meaning into consideration
2) the semantic type of the interaction and the contextual information about the interaction
allow us to filter unnecessary predications such as: NEGATIVE TREATS, NEGATIVE
ASSOCIATED WITH, etc.
To further refine the drug-disease pairs to be relevant for LBD, we used Timeline profiles to
narrow down the drug-disease pairs. Any potential drug-disease pair that occurs before either the
first occurrence of either the related drug-gene or gene-disease pair is excluded. Equation (1)
clarifies this use of a Timeline profile:

(Eq 1)

where Ysp(Drug-Gene) indicates the publications’ date of all Medline abstracts that contain at least
one semantic predication between Drug-Gene. For Drug-Disease pairs, we considered publications
that contain at least one co-occurrence of the entities (Yc). For example, assume four studies in
2002, 2004, 2007, and 2014 reported association between Drug A and Gene B; and two studies in
2007 and 2010 mentioned association between Gene B and Disease C. The left-hand side of
equation would be:
Max (Min (2002, 2004, 2007, 2014), Min (2007, 2010)) = 20067
So, if Drug A and Disease C appeared together in any publication before 2007, we do not consider
Drug A-Disease C. Figure 4 illustrates this example.
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Figure 4: Timeline profile. This figure illustrates the timeline profile which we used to make the generated drug-disease pairs
relevant to LBD. In this example, as drug-disease pair co-occurred in 2008 (for the first time), which is after both drug-gene and
gene-disease relations mentioned in literature, is an acceptable pair in our study.

4.2.2 Evaluating sentence and discourse-level relation extraction
In the next step, we search Medline abstracts for any co-occurrence (evidence) of drug and disease
pairs that were not filtered because of their place on the timeline. We categorize the drug-disease
pairs with at least one evidence in Medline into two groups, depending on whether they occur in
the same sentence or spanning multiple sentences
In order to assess the true validity of the drug-disease pairs, we compare the drug-disease pairs
identified by the system against the chemical-disease associations in the Comparative
Toxicogenomic Database (CTD) [99], a manually curated database of biological relations and
associated PubMed citations. A pair is considered valid only if the Medline abstract matches a
PubMed citation that contains the drug-disease pair.
Lastly, we perform an analysis to study whether discourse-level analysis would have a positive
impact on the time lag since the reporting of causal pairs (drug-gene/gene-disease) and the
appearance of drug-disease pair in the scientific literature.
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4.2.3 Results
4.2.3.1 Retrieval of LBD relations
There were a total of 1,710 approved drugs extracted from DrugBank [93]. Using this list of drugs,
from SemMedDB there were 4,096 unique drug-gene (A-B) pairs given the gene-related semantic
predicates extracted from SemMedDB. For all the genes mentioned in A-B pairs we retrieved
2,741 gene-disease (B-C) relations from SemMedDB. With gene being the common link between
Drug-Gene and Gene-Disease, we inferred 71,842 potential drug-disease (A-C) relations. The
results of the study are illustrated in Figure 5.

4.2.3.2 Comparison of sentence level and discourse level
We found only 37,719 (52.05%) of the 71,842 drug-disease pairs with at least one literature
evidence.
Timeline analysis (Eq1) further narrowed down the number of drug-disease pairs to 8,772
(23.25%) from 37,719. 6,450 drug-disease relation pairs (73.52%) out of 8,772 identified earlier
transcend sentence boundaries, demanding the requirement of discourse-level analysis for textual
extractions.
For the 2,322 pairs that co-occurred in at least one abstract at the sentence level, we found 89,805
total co-occurrences in the literature. Further composite analysis revealed that there was far more
literature evidence across sentences than from a single sentence as shown in Figure 6.
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Figure 5: Results of the study.

For the 8,322 drug-disease pairs, only 537 (6.4%) of them matched the gold standard, CTD. Further
analysis revealed that only 130 (24.20%) of the 537 that matched the gold standard occurred in a
single sentence while the rest (75.80%) appeared across different sentences. Ignoring the match,
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found in the literature citations we found 17,094 of the drug-disease pairs matched those in the
CTD.

Figure 6: Comparison of frequencies of drug-disease relations’ co-occurrence in a single sentence versus multiple
sentences

4.2.3.3 Discourse-level analysis may impact Time lag of LBD
Figure 7 plots the cumulative percentage which represents a cluster of drug-disease pairs observed
at a time zone at both the sentence level and discourse level. The trend shows that performing
discourse-level analysis would significantly advance the identification of the drug candidate for a
specific disease.
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4.2.4 Discussion
In this study, we assessed a method for finding potential drug candidates based on co-occurrence
of drug-gene pairs and gene-disease pairs within Medline Abstracts. The study also compared the
candidates found when considering relations found within a single sentence versus those spanning
multiple sentences and thus require some discourse-level analysis. We found that drug-gene and
gene-disease relations quite often transcend clausal and sentence boundaries and hence demand
mechanisms to connect information across such boundaries. Here we found the description of
23,268 potential drug-disease relations across sentence boundaries versus the 14,451 relations
within sentences.
Across all experiments, we observed a consistent trend that drug-disease relations that occurred
across sentences outnumbered the ones within sentences. Our evaluation against the curated CTD
resource also reinforces this trend. The study also revealed that a discourse-level analysis would
have significantly reduced the time lag between the scientific reporting of causal pairs (druggene/gene-disease) and drug-disease relational pair. This shows the need for advance discourselevel analysis approaches to extract information from literature in time and its ability to hasten the
pace of discovery.
Another significant observation is the amount of potential false-positive drug-disease relations
identified through literature mining. We observe a substantial reduction in the number of drugdisease relations when we compare the literature-based drug-disease pairs with those from curated
resource CTD (Figure 5). The reduction among the discourse-level pairs is far greater (3.3 times)
when compared to the ones from sentence level (2.5 times), which might reflect that the discourse
level analysis provided more candidates.
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Figure 7: Comparing the time gap between the first co-occurrence of discovery and the causal pairs (Sentence level

versus discourse level)

4.2.5 Summary
In this study, we investigated the extent of the need of discourse-level analysis for drug-disease
relation extraction from biomedical literature. We used Semantic Medline to extract LBDs and
then based on co-occurrence analysis, we collected any evidence of the discoveries in Medline
abstracts. We categorized the evidence into two categories, sentence level and discourse level.
From subsequent analysis, we infer that there is a potential to miss more than 70% of drug-disease
relations when we extract information from just the sentence level. This clearly demonstrates the
need for deeper discourse-level analysis, which may translate to significant improvement in the
state of the art of NLP techniques.
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4.3 Prioritization of potential discoveries generated by LBD
In the second part of this chapter, we study prioritizing drug repositioning candidates generated by
LBD systems. We propose and evaluate two prioritization approaches; 1) predicate-based 2)
context-based.

4.3.1 Predicate-based prioritization
In this study, we follow the same approach as in the previous study to build a LBD system which
generates a list of potential drug-disease relations using semantic predications in SemMedDB.
From the initial list, we explore a series of methods to eliminate erroneous extraction. We then
assign a score to the remaining pairs (likelihood of being true drug-disease pair) and rank them.
First, we remove pairs that were qualified by negated predicates such as “did not inhibit”. We also
remove pairs that were qualified by “co-exists” predicate, which does not semantically define a
relationship between the pairs. For ranking, we use the occurrence of predicates that qualify the
binary relationships (between drug-gene and gene-disease) as a feature to rank the final drugdisease relationships. For example, to rank this pair, Strepsils - Chagas, inferred from these
semantic predications:
•

Example 1) Strepsils (Drug), INTERACTS WITH, CA2 (Gene)

•

Example 2) CA2 (Gene), AUGMENTS, Chagas (Disease)

we use the predicate between drug-gene, “INTERACTS WITH”, and the predicate between genedisease, “AUGMENTS”. The semantic predicates of both the drug-gene and gene-disease pairs
(which we call intermediate predicates) play a determining role in qualifying a drug-disease pair.
We attempt to find a meaningful co-relation between the predicates, one that qualifies drug-gene
and gene-disease relationships, and the likelihood of generating a true drug-disease pair. The
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importance of predicate to determine the relevance of drug-disease relations is even more
important given the fact that the individual semantic predication can occur in more than one
document. In order to assert a relationship that is inferred from two relationships from multiple
documents, we propose that the predicate co-relation between the two relationships is one of the
key factors. Besides, the relation and the predicates may have many-to-many relationships
meaning that more than one predicate can qualify a relation between the two entities. For example,
there is only one citation for the relationship between Strepsils and CA2 (example 1), while there
are six citations that contain the relationship between CA2 and Chagas (example 2). Out of these
six, three of them are “ASSOCIATED WITH”, two of them are “AUGMENTS”, and one is
“AFFECTS” relationship.
To assign a score to each predicate, we take advantage of the existing curated resources. There are
numerous resources such as the UMLS and the Comparative Toxicogenomics Database (CTD)
[99], which catalog drug-disease relationships. In this study, we use UMLS as the gold standard
to evaluate the effect of intermediate predicates in generating a true drug-disease pair. To identify
already known drug-disease relations in the list generated by the LBD system, we cross-reference
the generated list of drug-disease pairs with UMLS drug-disease relations. We assign a score to
each predicate based on how many times they generate a true drug-disease pair.
We propose two different ranking approaches based on two assumptions. In the first approach, we
consider the predicate of drug-gene and gene-disease to be independent of each other, while in the
second we consider the dependencies between the predicates of the two pairs.

4.3.1.1 Method of ranking based on predicate independence
Figure 8 shows the steps of calculating the independence scores for each drug-disease pair. In the
first step, we use SemMedDB to retrieve drug-gene and gene-disease pairs and create a list of
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potential drug-disease pairs. Then we cross-reference the drug-disease pairs with true drug-disease
relations in UMLS. As our goal is to identify potential drug-repositioning candidates, we only
consider drug-disease relations in UMLS where their type is “May_be_treated_by”. As
SemMedDB stores Concept Unique Identifier (CUI), assigned by UMLS to each biomedical
entity, we use CUIs to cross-reference our list and UMLS. After identifying true drug-disease pairs
in our list, we go back to identify drug-gene and gene-disease pairs which created those drugdisease pairs. Then we count how many times each intermediate predicate contributed to
generating true drug-disease relations.
The score for a given drug-disease pair inferred from the individual pair (drug-gene (DG) and
gene-disease (GD)) is calculated as per the equation 1.
;

7

𝑃-/.016
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𝑆𝑐𝑜𝑟𝑒 = ' log +
4 + ' log +
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<9:

(1)

89:

Where:
n: the number of semantic predications between the drug-gene extracted from the literature
m: the same number for the gene-disease relationship
PpDG-U5: Percentage frequency of the predicates in drug-gene which participated in creating
drug-disease pairs appeared in UMLS
PpGD-U: Percentage frequency of the predicates in gene-disease which participated in
creating drug-disease pairs appeared in UMLS
PpDG-S6: Percentage frequency of drug-gene predicates in SemMedDB

5
6

The first “P” stands for percentage and the second one stands for predicate and “DG” stands for “Drug-Gene”.
In this notation, “S” stands for “SemMedDB”.

50

PpGD-S: Percentage frequency of gene-disease predicates in SemMedDB
We use (PpDG-S) and gene-disease (PpGD-S) to normalize the percentage frequencies (PpDG-U and
PpDG-S).

Figure 8: Steps of calculating independence scores
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For example, consider the above drug-disease pair (Strepsils - Chagas). In order to calculate the
score for the pair, we add the ratio of log scores of the individual predicates as outlined in equation
(1). For this example, we add the score of the only predicate, “INTERACTS WITH” that defines
the relationship between the drug-gene pair (Example 1) with the score of all six predicates
between the gene-disease pair (Example 2). As mentioned before, more than one predicate may
qualify a drug-gene/gene-disease pair, which we consider the summation of the ratio of log scores
of all of them. At this point, we do not consider the semantic relatedness of the predicates while
calculating their scores.

4.3.1.2 Method of ranking based on predicate inter-dependence
In the second ranking, we assume that the predicates of the drug-gene pair and the gene-disease
pair are dependent on each other while estimating their relevance in pairing a drug with a disease.
This changes the formula used to compute the final score. Here are the specific steps used to score
the pairs:
1) Compute the Percentage Frequency of the combined predicates between the drug-gene
and gene-disease pair (PpDG-pGD). We limit this calculation to only those drug-disease
pairs that are represented in UMLS drug-disease relations, which we indicate with this
notation (PpDG-pGD-U). For this computation, we count how many times each combined
predicate appeared in true drug-disease pairs (generated by the LBD) and then calculate
percentage frequency for them.
2) To normalize the percentages, we use the percentage frequency of the combined
predicates from SemMedDB (PpDG-pGD-S) as outlined in the following equation:
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89:

where n and m present the number of all different predicates between drug-gene
and gene-disease, respectively. #𝑝./ shows the frequency of the drug-gene
predicate in SemMedDB, and #𝑝/. shows the frequency of gene-disease.
3) Using the percentage frequency, we calculate the raw score for a given generated drugdisease pair as given in the following equation (3).
;

𝑆𝑐𝑜𝑟𝑒 = ' log +
<9:

𝑃-./0-/.012
4
𝑃-./0-/.032

(3)

where n presents the number of combinations which generate that drug-disease pair
which is equal to the product of the number of different predicates between the
drug-gene pair and the number of predicates between the gene-disease pair.

4.3.1.3 Validation and evaluation
To validate our ranking methods, we use two resources, CTD and Medline citations. After the
scoring, the drug-disease pairs are sorted according to the scores, with the highest scoring pairs
first. We then calculate and compare the percentage of high ranked and low ranked pairs that occur
in the CTD or co-occurred in Medline abstracts.
We cross-reference the generated drug-disease with CTD and then using a statistical test, calculate
the correlation between our ranking methods and being a true drug-disease pair (appearing in
CTD). We also measure the correlation between the score assigned to each generated pair and the
number of times that the pair co-occurred in Medline abstracts. As the last step of validation, an
expert reviewed the top 10 ranked drug-disease pairs manually by conducting a web-based search
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for each of these pairs and reviewed the relevant scientific literature to identify type of relation
between the pairs.

4.3.1.4 Result
All drug-gene and gene-disease semantic predications were retrieved from SemMedDB. There
were 19,993 drug-gene pairs (12,666 unique) and 59,945 gene-disease pairs (33,489 unique).
When we applied Swanson’s model to these pairs, it resulted in the generation of 653,108 potential
drug-disease pairs (245,102 unique). Of the roughly 245,000 possible pairs, we found that about
0.5% (N=1,204) of the generated pairs appeared in UMLS. These 1,204 pairs were used to
calculate percentage frequency related to each drug-gene and gene-disease predicate.
Figure 9 shows the percentage of high and low ranked drug-disease pairs, which co-occurred in
Medline abstracts, for the both, inter-dependence and independence, methods. In this figure, the
Y-axis shows the percentage of pairs that co-occurred in Medline and the X-axis shows the number
of top ranked pairs. Using a T-test, we found that the inter-dependence method (shown in red) was
significant P value < 2.2e-16.

Figure 9: Comparison of the percentage of high and low ranked drug-disease pairs co-occurred in Medline abstracts.
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Figure 10 shows the results of calculating the percentage of appearance of just the high and low
ranked drug-disease pairs in CTD.

Figure 10: Comparison of the percentage of high and low ranked drug-disease pairs appeared in CTD.

Table 7 includes the result of our manual investigation of top ten ranked drug-disease pairs.
Table 7: Top ten ranked drug-disease pairs

Drug

Disease

Type

Reference

Omalizumab

Asthma

Treatment

[100]

Nifedipine

Tetanus

Treatment

Wikipedia

Nifedipine

Ischemia

Treatment

[101]

Omalizumab

Dermatitis, atopic

Treatment

[102]

Nifedipine

Heart failure

Treatment

[103]

Nifedipine

Renal tubular disorder

Relation

[104]

Calan

Hypertensive disease

Treatment

Not found
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Airol

Asthma

-

Not found

Ezetimibe

Coronary heart disease

Treatment

[105]

Cyclosporine

Asthma

Treatment

[106]

4.3.1.5 Discussion
In the prioritization study, we found that the interdependence-based rankings of drug-disease pairs
(especially the top ranked pairs) identified through LBD were much more likely to be supported
by published evidence than the pairs ranked using the independent ranking approach. Figure 9
shows that 82% of the top 100 drug-disease pairs, ranked using inter-dependence approach had
supporting literature-based evidence. These pairs were found to co-occur within a single abstract
in Medline. However, there is a noticeable decline in the percentage of pairs as the ranking goes
below 100. We observed that pairs ranked using independent ranking approach had relatively
lower co-occurrence evidence in the biomedical literature.
We observed a similar trend when we evaluated the confidence levels of the top ranked pairs
identified using both approaches against the CTD. Figure 10 further confirms the distinct
advantage of the inter-dependence ranking over the independence ranking. Finally, manual
evaluation of top ten pairs ranked by inter-dependence approach revealed that the pairs have some
biological significance based on expert judgment. This indicates that the inter-dependence method
would be useful for identifying biologically relevant drug-disease pairs. Moreover, nine out of ten
top ranked drug-disease pairs were found to belong to DRUG-TREATS-DISEASE relationship
category.
There are two main limitations in this study. First, we did not have a gold standard of drug-disease
treatment pairs to evaluate the performance of our approaches. Second, there is an inherent
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limitation both in the choice of resource (choice of CTD as a resource) and the measure (literature
co-occurrence) to evaluate the confidence levels of top ranked drug-disease pairs identified by the
system. CTD though a manually curated resource does not annotate the type of relationship
between the drug and disease. Hence while evaluating our system against CTD we ignored the
semantic predications extracted by the system, which would have resulted in loss of valuable
information. Alternatively, we relied on document level co-occurrence in literature as a measure
to validate drug-disease relationship. Document level co-occurrence of a relation is not a strong
indicator for a valid drug-disease relation. There are also limitations in our ranking methods. Using
some rigorous statistical validation may further refine the notion of semantic predication as
evidence for relation between biomedical entities for LBD.

4.3.1.6 Summary
In this study, we proposed and evaluated two methods for ranking and prioritizing potential drugrepositioning discoveries extracted from literature. We used drug-gene and gene-disease
predications, extracted by SemRep, to generate potential drug-disease pairs. The predicates
between dug-gene and gene-disease pairs are used to rank the generated drug-disease pairs. Our
results showed using combination of drug-gene and gene-disease predicates can be a metric to rank
more likely true drug-repositioning candidates higher in the list.

4.3.2 Context-based prioritization
In the second study related to prioritization, we propose a new method, called context-based
prioritization. This method utilizes text surrounding A-B and B-C relations (causal
associations/findings), to prioritize discoveries generated by LBD systems.

57

While our previous method (Study 2 in this chapter) looked for evidence in the form of sematic
predications, in this approach, we explore a ranking method that utilizes text surrounding causal
findings to train a binary classifier that categorizes drug-disease pairs into the following two
classes:
a) Positive class (Likely a true drug repositioning candidate)
b) Negative class (Unlikely a true candidate)
The classifier uses two sentences, which drug-gene and gene-disease relations are extracted from,
to classify generated drug-disease pairs into one of these two classes.

4.3.2.1 Method of context-based prioritization
Like the two previous studies in this chapter, we use drug-gene and gene-disease semantic
predications to generate potential drug-disease pairs. Like previous studies, we follow Swanson’s
model in our LBD system (more details in section 2.1).
After generating the list of drug-disease pairs, we search these relations in SemMedDB. We
consider a drug-disease pair as a positive instance, if there is any semantic predication in
SemMedDB that shows treat relationship (predicate) between that drug and disease. The rest of
drug-disease pairs in the list, are considered as negative instances.
We randomly select 5000 drug-disease pairs (2500 positive and 2500 negative instances). We
retrieve two sentences from Medline abstracts for each of the pairs:
a) one sentence which contains the corresponding causal drug-gene pair
b) one sentence which contains the corresponding causal gene-disease pair
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To address the possible time gap between appearing causal pairs (drug-gene and gene-disease) and
evidence of drug-disease pair in literature (discussed in section 2.1), we only select the drugdisease pairs with causal relationships published before 2009. To generate some of drug-disease
pairs, more than one gene can play role of linking entity. For those drug-disease pairs, we randomly
select only one gene.
In the next step, we use these 5000 pairs and the sentences, corresponding to their causal pairs, to
train a classifier.

4.3.2.1.1 Features and learning models
We generate two separate sets of features for each of causal pair, however they contain similar
features. For each causal pair and corresponding sentences, the following features, determined
after some preliminary analysis, are used in the classifier:
1. Words that appeared at least 10 times in the causal sentences
2. Bi-grams that appeared at least 5 times in the causal sentences
3. Tri-grams that appeared at least 5 times in the causal sentences
4. Predicate between the entities
To find the optimal learning model, we compare several common models such as: Random Forest,
Naïve Bayes, Support Vector Machine, Decision tree (J48 algorithm) and Rule-based (JRip
algorithm). We implement the classifier in Java and use Weka training models [107].

4.3.2.1.2 Ranking
After training, the classifier is used to rank generated drug-disease relations by the LBD system.
For each drug-disease relation, we take the three following steps:
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1) Classify all pairs of causal sentences, which might lead to a relation (some drug and
disease pairs can be inferred by more than one gene and also each drug-gene or
gene-disease pair can be extracted from more than one sentence)
2) Count the pairs of causal sentences classified as positive (positive instances) for
each drug-disease pair
3) Rank the drug-disease pairs based on number of positive instances (in descending
order). In case of a tie, the linking term count [90] is used to rank the pairs (in
descending order).
As the aim of LBD is to discover novel findings, we only rank potential novel drug-disease
relations and remove already known relations. We consider a drug-disease relation as already
known relation, if there is at least one semantic predication that shows relationship between them.

4.3.2.2 Evaluation
We evaluate the classifier and the ranking approach separately.

4.3.2.2.1 Classifier
To evaluate performance of the classifier and find the best learning model, the common metrics,
precision, recall, and F-Measure are used.

𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =

𝑅𝑒𝑐𝑎𝑙𝑙 =

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
(𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒)

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
(𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒)
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𝐹 − 𝑀𝑒𝑎𝑠𝑢𝑟𝑒 =

2 ∗ (𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑅𝑒𝑐𝑎𝑙𝑙)
(𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙 )

The classifier is evaluated using 10-fold cross validation.

4.3.2.2.2 Ranking method
To evaluate the ranking method, we generate a test dataset containing drug-disease pairs where
their causal drug-gene and gene-disease pairs appeared after 2009 in the literature. We rank these
pairs using the classifier and use the ranked list to evaluate our method. Firstly, we study
distribution of known drug-disease relations (pairs with at least one evidence predication) in the
list.
Secondly, we calculate the two following correlations (using a t-test) between actual class labels
(based on evidence predications in SemMedDB) and the following:
1) Number of instances classified as positive
2) Difference of number of instances classified as positive and negative
Thirdly we compare our ranking method with the LTC [69] method. For this comparison, we rank
the pairs in the test dataset using both methods and compare the distribution of true pairs in the
ranked pairs.
In addition to drug repositioning, we assess our method for two other tasks
1) identifying novel adverse drug reaction (ADR)
2) identifying existence of relation between drug and disease (regardless of relation type).
To train the classifier for identifying ADR, drug-disease pairs augmented with “predisposes”,
“disrupts”, “complicates”, and “causes” predicts are considered as positive instances and the
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others as negative. For latter one, we use CTD [99] to label instances as positive or negative,
instead of using the SemMedDB.

4.3.2.3 Results
We retrieved all drug-gene and gene-disease semantic predications from SemMedDB, which
yielded 19,993 drug-gene and 59,945 gene-disease pairs. Following Swanson’s model, 245,102
unique potential drug-disease relations were generated. Table 8 shows the performance of the
classifiers trained using different training models for the drug repositioning task. Table 9 illustrates
the performance of the classifier for identifying adverse drug events and Table 10 shows the
classifier performance for identifying the relation between drug and disease, regardless of relation
types. All these tables show the results of 10-fold cross validation.
Table 8: The performance of the classifier for drug repositioning task

Training Model

Precision

Recall

F-Measure

Random Forest

0.785

0.781

0.782

Naïve Bayes

0.688

0.685

0.686

SVM

0.708

0.712

0.709

J48

0.709

0.714

0.711

JRip

0.686

0.677

0.681

Our calculation showed that there are strong positive correlations between the actual class label
and the a) number of positive pairs of causal sentences (p-value = 2.2e-16) and the b) difference
between the number of positive and negative pairs (p-value = 1.005e-07).
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Table 9: The performance of the classifier for adverse drug event task

Training Model

Precision

Recall

F-Measure

Random Forest

0.8646

0.8600

0.8622

Naïve Bayes

0.7825

0.7819

0.7821

SVM

0.7281

0.7123

0.7201

J48

0.7471

0.7472

0.7471

JRip

0.7910

0.7562

0.7732

Table 10: The performance of the classifier for identifying relation between drug and disease task

Training Model

Precision

Recall

F-Measure

Random Forest

0.8357

0.833

0.8343

Naïve Bayes

0.6895

0.688

0.688

SVM

0.673

0.681

0.6769

J48

0.7699

0.7422

0.7557

JRip

0.6953

0.693

0.6941

Out of 245,102 drug-disease pairs, 6205 pairs met the test dataset criteria. We found out that 180
pairs in the test dataset were true drug-disease pairs (treatment relationship). Figure 11 shows the
number of true drug-disease pairs in the ranked test dataset. Each interval shows the number of
true pairs in that interval.
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Figure 11: Number of true drug-disease pairs in different intervals of ranked test dataset

We compared true drug-disease pairs in top 100 pairs ranked by LTC and our method. There were
20 true drug-disease pairs in top 100 pairs ranked by our method and only 13 pairs in the pairs
ranked by LTC. Figure 12 shows result of this comparison and intersection of true drug-disease
pairs in top 100 pairs. We observed a similar trend in the top 500 pairs. Our method ranked the 58
true pairs in the top 500 pairs and LTC ranked 42 true pairs (38 pairs in common).

4.3.2.4 Discussion
Table 2, 3, and 4 show the performance of our classifier. The performance reported in Table 8
confirms that using the surrounding text of drug-gene and gene-disease causal relations can help
determine the likelihood of being a true drug repositioning candidate for generated drug-disease
pairs. Using the random forest model, the classifier obtained f-measure of 0.78, which is a
reasonable performance for a classifier for a task of this complexity. The performance of the
classifier for two other tasks, identifying adverse drug events and relation detection, also supports
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the proposed approach. Random forest achieved the highest f-measure among the five learning
models for those two tasks, 0.86 for adverse drug event (Table 9) and 0.83 for relation detection
(Table 10). As two different public resources are used as silver standard datasets (SemMedDB and
CTD) to train and test the classifiers for these tasks, the results demonstrate that the performance
of the classifier is not dependent on the particular dataset.

Figure 12: Comparing true drug-disease pairs in top pairs ranked by (A) our method and (B) LTC.

However, we found strong correlations between the actual class label and both the number of
positive instances and the difference between the number of positive and negative instances, but
the correlation between actual class label and earlier is stronger. These results support using the
number of instances classified as positive in our ranking method.
After ranking drug-disease pairs in our test dataset, we studied the distribution of true drug
repositioning pairs in the list and as Figure 11 shows, the top ranked pairs include most of the true
pairs. We identified 32% (58 out of 181) of the true drug repositioning pairs in the top 8% (500
out of 6000) of ranked pairs. We plotted this distribution for both our ranking and LTC methods
in Figure 11. The distributions showed that our approach ranked more true pairs in top of the list
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comparing to LTC method. The next comparison illustrated intersection between top ranked true
drug repositioning pairs by both methods. Part 1 in Figure 12 demonstrates that our method was
able to rank 84% (11 out of 13) of true drug repositioning pairs ranked by LTC in top 100, in its
own top 100 pairs. This number for top 500 pairs (part 2, Figure 12) was even higher 92% (38 out
of 42). These two Venn diagrams clearly demonstrate that the majority of true pairs are in common
between both methods, but our method was able to rank more true pairs in higher ranks of the list.
There are two main limitations in this study, which first one is the lack of access to a gold standard,
the same as in the previous study. Another limitation is using a balanced dataset (50% positive and
50% negative cases) for training the classifiers. At this point, we have not trained/evaluated our
classifiers using an unbalanced dataset.
However, the results show that our proposed method can play a role in prioritizing LBD findings,
but still provide pharmaceutical companies with a long list of potential candidates. As future work,
we plan to not only prioritize the candidates, but also identify and remove false positive candidates
from the list.

4.3.2.5 Summary
In this study [108], we created and tested a new method to prioritize discoveries identified by our
LBD system. Our LBD system, which is based on Swanson’s model, uses semantic predications
as causal findings to hypothesize new findings. To rank the generated hypotheses, we trained a
binary classifier using information surrounding causal findings in literature. We trained our
classifier for three different purposes, drug repositioning, adverse drug event, and drug-disease
relation detection. Our classifier obtained reasonable f-measures for all the tasks (respectively,
0.78, 0.86, and 0.83). Our results showed that the proposed method performed better than one of
previous methods in ranking true drug repositioning candidates at the top of the list.
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Chapter 5: Using biomedical literature and
clinical trials to prioritize potential
candidates
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5.1 Introduction
In chapter 4, we studied two ranking methods for potential drug repositioning candidates generated
by LBD systems. In this chapter, we study ranking the candidates generated by information from
a different source, phenome-wide associations studies (PheWAS). The goal of this chapter is to
assess this method of using text data in prioritizing non-LBD discoveries.
PheWAS provide evidence for the association of genetic variants with a wide spectrum of human
disorders[109]. The PheWAS strategy relies on electronically available phenotypic data collected
from patient cohorts. PheWAS is similar to a genome-wide association study (GWAS), but
whereas a GWAS asks “What genetic variants are associated with a disease?”, a PheWAS asks
“What diseases are associated with a genetic variant?”. PheWAS, similar to GWAS, provides us
a list of gene-disease associations which we utilize to generate a list of potential discoveries.

5.1.1 Related works of Phenome-Wide Association Studies
In 2010, Denny et al. [45] introduced PheWAS and demonstrated an approach to discover genedisease associations using genetic data coupled to longitudinal electronic medical records. Later,
Nature Biotechnology published a study by Denny et al. [110] in which they conducted a
comprehensive PheWAS on 3,144 single-nucleotide polymorphisms (SNPs) that had been
previously associated with a variety of phenotypes by GWAS. This PheWAS, like many other
PheWAS published [109]–[111] used International Classification of Diseases version 9 (ICD9)
codes extracted from electronic medical record systems in large patient cohorts to define casecontrol groups for many phenotypes. In the United States, ICD9 coding is primarily used for billing
and can have variable effectiveness for describing discrete phenotypes. Regardless, Denny et al.
[110] demonstrate that for many of the GWAS SNPs, PheWAS was able to rediscover expected
SNP- disease associations while also identifying novel associations [110]. This suggests that
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PheWAS results may also provide new opportunities to identify candidates for drug repositioning.
However, it is also likely that false positives exist in the reported PheWAS data, especially for
those SNP-disease associations with moderate evidence of association. Independent PheWAS may
prove highly effective when replicating novel findings. Regardless, to balance accuracy while still
allowing for discovery and hypothesis generation, one might choose a loose P-value threshold
from PheWAS data.

5.1.2 GWAS vs PheWAS in drug repositioning
As mentioned before, drug repositioning is the process of discovering new indications for existing
drugs [112]. Critical to drug repositioning is the initial identification of candidate drug-disease
relationships. Genetic-based association studies, including GWASs, have proven to be effective
for generating hypotheses related to drug repurposing [113], [114]. GWASs can identify disease
susceptibility genes that are targets for existing drugs used to treat different conditions. For
example, a large GWAS implicated flavopiridol, a CDK4 inhibitor and anti-cancer agent, as a
possible drug to repurpose for the treatment of rheumatoid arthritis [115]. However, GWAS data
is partly limited by the number of diseases that can be linked to a gene. A unique advantage of the
PheWAS approach is the ability to measure genetic associations with thousands of diseases
simultaneously, which may be ideal when identifying pleiotropic effects. As a result, PheWAS
may prove to be an effective alternative to GWAS when identifying susceptibility loci.
Importantly, PheWAS may further expand the horizon for discovery and prioritization of
candidates for drug repositioning [116].

5.2 Method
We seek to demonstrate the potential use of PheWAS information for drug repositioning by crossreferencing PheWAS data with biomedical databases.
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5.2.1 Generating Candidates
We begin by extracting all SNP-disease associations from the recently reported PheWAS by
Denny et al. [110]. We filter the association based on P-value. We use a loose P-value threshold
(P ≤ 0.05). Only those SNPs that are mapped directly to a gene according to dbSNP, which includes
2 kb upstream and 500 bp downstream, are considered in the study. In the next step, we retrieve
all drugs from DrugBank and their direct and indirect gene targets and generate a list of drug-gene
relations. These drug target data have been previously applied to other in silico drug-screening
studies [117]–[119]. Then, we look for all sets of transitive pairs, A-B, B-C where A-B is a diseasegene pair from PheWAS and B-C is a gene-drug pair from DrugBank. (Figure 13).

Figure 13: The three steps in the discovery process. (1) PheWAS associations [108] to connect diseases to genes; (2) DrugBank
analysis to connect genes to drugs; and (3) drug repurposing targets that connect drugs with diseases. Highlighted is an example
where this process rediscovered glyburide as an indication to treat type 2 diabetes.
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5.2.2 Validation and Ranking Candidates
To measure the relevance of the generated drug-disease pairs identified using PheWAS data under
a loose P-value cutoff, we assess the co-occurrence of the drug and disease terms in Medline
abstracts. For this purpose, MetaMap [95], is used to extract disease names from the PheWAS
phenotypes and then we scan Medline abstracts for the paired drug-disease terms using a text
search engine, Apache Lucene.
To validate our method, we generate a list of drug-disease pairs (the same number of pairs as our
method generated) where both drug and disease names are randomly selected from a list of drugs
and diseases. Then we follow the same approach to identify any co-occurrence of these pairs in
biomedical literature. Finally, we compare the percentage of the pairs in both lists which have at
least one co-occurrence in literature. We repeat the process 1000 times and look for any significant
difference in the percentages.
For comparison purposes, the process is also performed using gene-disease pairs driven solely by
GWAS data extracted directly from the GWAS catalog [120].
To assess the novelty of the drug-disease pairs and to better rank candidates for drug repositioning,
we further cross-reference all pairs with the clinical trial registry (clinicaltrials.gov). We categorize
the pairs into four categories, including:
•

known/rediscovered

•

strongly supported (some support in the literature and clinical trial registry)

•

likely (some support in the literature or clinical trial registry)

•

novel (no evidence in the databases)
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5.3 Result
We extracted all 212,851 SNP-disease associations from PheWAS catalog [110]. Only 1,501 SNPs
were mapped directly to a gene according to dbSNP, which allowed us to identify 48,488 unique
gene-disease relationships. Using gene-drug relations in DrugBank, we were able to identify
52,966 drug-disease pairs.
Of the 52,966 drug-disease pairs, 14,816 (28%) were supported in the literature. After permuting
drug-disease pairs 1,000 times and cross-referencing random drug-disease pairs with Medline
abstracts, we identified a total of 3,270 ± 57 drug-disease pairs (6.2%; Figure 14-a) that cooccurred in literature, which suggests that PheWAS data significantly enriches information for
drug-disease pairs supported by evidence. Of the 52,966 drug-disease pairs, 127 pairs were
‘rediscovered’ according to original indications listed in DrugBank (Table 11). As an example, the
PheWAS catalog reported an association between SNP rs2515629 and ‘type 2 diabetes’ (P =
0.000732). A search of dbSNP maps rs2515629 to the gene ABCA1, which is mentioned in
DrugBank as a gene target for glyburide, a drug used to treat type 2 diabetes. Therefore, this
process appropriately identified type 2 diabetes as an indication for glyburide (Figure 13). By
contrast, using the GWAS approach, the number of drug-disease pairs identified was 7,945 of
which 3,087 (38.8%) co-occurred in at least one abstract (Table 11). When the same permutation
procedure was established for the GWAS data, a total of 489 ± 21 pairs (6.2%) appeared at least
once in the abstracts (Figure 14-b).
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Figure 14: Co-occurrence distribution plotted for 1000 randomly permuted drug-disease pairs identified in
Medline Abstracts for (A) PheWAS- and (B) GWAS-derived data. For each dataset, the number observed drugdisease pairs with evidence in Medline Abstracts is also highlighted. This contrast demonstrates that there is a
significant difference between the observed drug-disease pairs in Medline Abstracts from those randomly
permuted.

The resulting distribution of the 52,966 PheWAS-derived pairs and 7,945 GWAS-derived pairs
into the four categories of discovery, are shown in Table 11.
Table 11: Comparison of PheWAS- and GWAS-based approaches to drug repositioning

Drug-Disease pairs

GWAS

PheWAS

7945

52,966

140 (1.8%)

127 (0.2%)

Drug indication type
Known/rediscovered
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Strongly supported

908 (11.4%)

2,583 (4.9%)

Likely

2,060 (25.9%)

12,221 (23.1%)

Novel (candidates for drug repositioning)

4,837 (60.9%)

38,035 (71.8%)

Some examples from each category driven by PheWAS data are illustrated in Table 12. For
example, PheWAS results indicate that SNP rs2736100 in the gene TERT is associated with
diabetes (P = 0.00029). Zidovudine, a drug prescribed to treat HIV/AIDS, is a reverse transcriptase
inhibitor and may inhibit TERT activity. This example suggests that zidovudine might be
repositioned to treat diabetes, a not unreasonable assertion as increased telomerase activity has
been reported to be associated with increased diabetes complications [121]. It should be noted that
the co-occurrence of drug-disease pairs may also be the result of adverse drug events [122].
Table 12: Examples of Drug-Disease pairs identified from PheWAS data
Medline
Citations/
Clinical Trial
Citations
(count)

Status

Drug

Disease
Indication

PheWAS
SNP

PheWAS
P-value

Associated
Gene

Known

Paclitaxel

breast cancer

rs242557

0.041

MAPT

3003/321

Known

Glyburide

type II diabetes

rs2515629

0.00073

ABCA1

240/12

Strongly
supported
Strongly
supported

Dexametha
sone

rheumatoid
arthritis

rs4795067

0.050

NOS2

4271/48

Everolimus

breast cancer

rs17036350

0.040

MTOR

221/46

Likely

Verapamil

vaginal cancer

rs216013

0.011

CACNA1C

1144/0

Likely

Chlorprom
azine

liver cancer

rs11214606

0.033

ARVCF

423/0

Novel

Porfimer

hypercholesterolemia

rs6511720

2.5E-6

LDLR

0/0

Novel

Zidovudine

diabetes

rs2736100

0.00029

TERT

0/0
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5.4 Discussion
This study offers many promising new candidates to explore. Complete results from this study are
available to the scientific community for further experimental validation and clinical study [22],
[23]. For example, an investigator interested in developing a new drug for breast cancer would
have 18 candidates, including oxcarbazepine and disopyramide, for investigation. Similarly, new
indications may be identified for existing medications. On the basis of our analysis, docetaxel has
88 potential new indications, including psoriasis, migraine and osteoporosis.
Because the SNPs selected for the PheWAS were derived from reported GWAS, it is not surprising
that several drug-disease pairs identified by PheWAS overlap those identified by GWAS.
Specifically, there were 161 overlapping drug-disease pairs between GWAS and PheWAS data;
70 were initially identified as ‘novel’ (no evidence in the databases). The 161 overlapping pairs
may be an under- representation of the true overlap as phenotypic terms used by the GWAS may
differ from those defined by the PheWAS, especially GWAS that assessed quantitative traits. For
example, the PheWAS identified a link between LDLR, a target for Porfimer [93], and “hypercholesterolemia,” whereas GWAS connected LDLR to “cholesterol” (Table 11).
As mentioned previously, we chose a loose P-value threshold for PheWAS data for discovery and
hypothesis generation. On the basis of permutation analysis, many of these associations may be
real,

but

these

are

undoubtedly

mixed

with

false

positives.

We

investigated

the effect of various P-value thresholds. When using a P-value threshold of ≤ 0.001, approximately
250 drug-disease pairs with evidence were observed. This more stringent P-value threshold may
decrease false positives but also dramatically reduce the number of potential candidates.
Interestingly, as P values decreased below 1.0 × 10–5, the proportion of drug-disease pairs with
evidence in the literature increased (Figure 15). Additional replication of PheWAS findings should
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improve the association results. Furthermore, incorporating other biomedical databases, such as
SemMedDB [78] and the Drug-Gene Interaction Database [123], in combination with manual
curation, may also significantly benefit the prioritization process.

Figure 15: Number of drug-disease pairs by P-value threshold for those pairs with and without evidence according to Medline
Abstracts, Clinical Trial Registry, or DrugBank.

Even with many drug-disease pairs identified through this raw screen, other factors of course
influence whether candidates for drug repurposing may be suitable for commercial development.
Economic factors may limit some drug candidates. Pharmaceutical companies may not support
drug repositioning due to insufficient market potential driven by disease frequencies, competing
medications, and/or intellectual property protection. In addition to economic constraints, some
agents may require reformulation due to therapeutic index, toxicity profile and/or agent type
(topical agents versus systemic agents). A second level ‘screen-out’ approach would further help
identify candidates for repositioning.
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5.5 Summary
The conclusions of this study are two-fold. First, we suggest that the utilization of PheWAS data
provides a robust approach for identifying new drug candidates for repurposing. Second, we
illustrate how to use biomedical literature and clinical trials to rank non-LBD drug repositioning
candidates. In this study, we identified nearly 14,800 drug-disease pairs with some evidence of
support in biomedical literature or clinical trials. In addition, we identified more than 38,000 novel
candidates for re-purposing, encompassing hundreds of different disease states and over 1,000
individual medications. We anticipate that these results will be highly useful for hypothesis
generation in the field of drug repurposing.
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Chapter 6: Conclusion
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6.1 Introduction
The drug development process is a prolonged and expensive process. In this thesis, we examined
drug repositioning as a popular alternative approach to reducing the cost and time needed for
developing a new drug. We explored the opportunity of identifying potential drug repositioning
candidates by leveraging publicly available text-based resources. We conducted five studies and
utilized reviews posted by patients to WebMD, abstracts from the biomedical literature, clinical
trials, and PheWAS data as the main resources for generating and prioritizing the potential drug
repositioning candidates. We developed a rule-based system and studied the feasibility of using
patient reviews in drug repositioning. To our knowledge, this is the first study to consider using
social media data for this purpose. We were able to detect several beneficial effects of medications
reported by patients, which highlighted the value of social media in drug repositioning.
In three studies, we focused on literature-based discovery. First, we presented a method to compare
the relative importance of using either isolated sentences or multiple sentences comprising a
discourse to identify potential candidates. We found that nearly three quarters of the findable
candidates would require mining candidates using multiple sentences. In the other two studies, we
proposed statistical methods to prioritize the potential candidates. In the first method, we utilized
predicates in semantic predications extracted from Medline abstracts to rank the candidates. Our
results illustrated that predicates can be a metric to rank more likely true drug-repositioning
candidates higher in the list, however this approach is limited to LBD systems that utilize semantic
predication for discovery. The other method utilized the text surrounding discoveries to train
several classifiers and used the classifiers to score and rank the potential candidates. Our analysis
showed the effectiveness of this method as well. These two studies illustrated that by using
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computational methods and existing knowledge sources, we can rank and narrow down the long
lists of the potential candidates generated by LBD systems.
In the fifth study, we utilized text data to prioritize and categorize potential drug repositioning
candidates generated by a non-LBD system. In this study, we used Phenome-Wide Association
Studies to generate a list of potential candidates and then utilized text from the biomedical
literature and clinical trials to categorize and prioritize the candidates. The results of this study
showed that PheWAS can be used to generate new hypotheses for drug repositioning and that
biomedical literature and clinical trials can be used to prioritize the candidates and filter out already
known candidates.

6.2 Comparison
In this section, we will compare the systems presented in this thesis based on the number of
potential drug repositioning candidates generated by each. We presented three main systems to
generate the potential candidates: 1) LBD using semantic predication, introduced in chapter 4 2) a
PheWAS based system, presented in chapter 5 and 3) a GWAS based system, introduced in chapter
5 as well. Table 13 and figure 16 show the number of potential candidates generated by each
system, and the percentage of the candidates categorized as known, supported in literature (based
on co-occurrence of drug and disease), and novel.
Table 13: Comparing the systems based on the number of generated candidates
System
LBD using sematic
predication
PheWAS based

Total number
245,102

GWAS based

7,945

52,966

Already known
1,204 (0.49%)
(in UMLS)
127 (0.2%)
(in DrugBank)
140 (1.8%)
(in DrugBank)
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Supported in literature
53,922 (22%)

Novel
189,976 (77.5%)

14,816 (28%)

38,035 (71.8%)

2,963 (37.3%)

4,837 (60.9%)

Figure 16: Comparing the systems based on the number of drug repositioning candidates

By examining the results in Table 13, it is clear that the LBD system generated more potential drug
repositioning candidates than the others, but it provided the smallest percentage of candidates
supported by evidence from the literature. The GWAS-based system generated only 7,945
candidates with 37.3% supported by the literature, which suggests a lower false positive rate, but
has a limitation of generating the smallest number of novel candidates. Figure 14 indicates that for
all three systems, the biggest proportion of the candidates are novel and thus there is a need to
prioritize them and remove false positive candidates.
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6.3 Future work
In this thesis, we assessed methods for leveraging three important text-based resources, social
media, biomedical literature, and clinical trials. We did not include one of the most important textbased resources now available, clinical notes, because they are not public. Exploring clinical notes
as resource to identify and prioritize the potential candidates is a potentially valuable extension to
this work, as they might provide the earliest evidence of off-label uses of prescribed medications.
For each study described here, we mentioned the limitations which could be considered as potential
future work. For example, for the social media study, as we only explored the feasibility of using
social media for drug repositioning, and only considered data from one source, many extensions
are possible such as: exploring the other websites (tweeter, Facebook, …), creating an annotated
dataset and developing statistical methods, using state-of-the-art NLP algorithms to address known
issues with consumer-generated text, such as mis-spellings and ungrammaticality. To address the
need for better methods for prioritizing candidates and removing more false positives, the next
step would be to explore incorporating other biomedical databases, such as SemMedDB [78] and
the Drug-Gene Interaction Database [123], in combination with manual curation.
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